How Trump’s selection of RFK Jr. as HHS secretary could impact the pharma sector

Jared Holz, healthcare sector strategist at Mizuho Securities America, and CNBC’s Angelica Peebles join ‘Power Lunch’ discuss pharma stocks’ reaction to Robert F. Kennedy Jr.’s appointment to lead the Department of Health and Human Services, what the incoming administration could mean for regulation in the sector, and more.